Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: A case report

Wiener Klinische Wochenschrift

Volumn 123, Issue 1-2, 2011, Pages 61-64

  Pinter, Matthias ^a   Sieghart, Wolfgang ^a   Reisegger, Michael ^a   Wrba, Friedrich ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Cholangiocellular carcinoma; Multikinase inhibitor; Sorafenib

Indexed keywords

ANTIBIOTIC AGENT; B RAF KINASE; K RAS PROTEIN; SORAFENIB; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CASE REPORT; CHOLANGITIS; DIARRHEA; DISEASE COURSE; DRUG TOLERANCE; FATIGUE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; SKIN TOXICITY; SYMPTOM;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHOLANGIOCARCINOMA; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES; TREATMENT OUTCOME;

EID: 79952282097     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1522-y     Document Type: Article

References (21)

1. MJ Olnes R Erlich 2004 A review and update on cholangiocarcinoma Oncology 66 167 179 10.1159/000077991 15218306 (Pubitemid 38813042)
2. WR Jarnagin Y Fong RP DeMatteo, et al. 2001 Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma Ann Surg 234 507 517 1:STN:280:DC%2BD3MrisFCqtA%3D%3D 10.1097/00000658-200110000-00010 11573044 discussion 517-509 (Pubitemid 32946713)
3. YH Shaib JA Davila L Henderson, et al. 2007 Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study J Clin Gastroenterol 41 911 917 10.1097/MCG. 0b013e31802f3132 18090160 (Pubitemid 350307078)
4. JC Tan NG Coburn NN Baxter, et al. 2008 Surgical management of intrahepatic cholangiocarcinoma - a population-based study Ann Surg Oncol 15 600 608 10.1245/s10434-007-9627-x 17987347
5. RM Goldstein M Stone GW Tillery, et al. 1993 Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 166 768 771 1:STN:280: DyaK2c%2FpvFCgsg%3D%3D 10.1016/S0002-9610(05)80696-8 8273866 discussion 771-762 (Pubitemid 24309361)
6. F Eckel RM Schmid 2007 Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 896 902 1:CAS:528: DC%2BD2sXjt1SrsLw%3D 10.1038/sj.bjc.6603648 17325704 (Pubitemid 46452283)
7. J Valle H Wasan DH Palmer, et al. 2010 Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 1273 1281 1:CAS:528:DC%2BC3cXksVyiuro%3D 10.1056/NEJMoa0908721 20375404
8. MT Carriaga DE Henson 1995 Liver, gallbladder, extrahepatic bile ducts, and pancreas Cancer 75 171 190 1:STN:280:DyaK2M%2FpsVWhsg%3D%3D 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2 8000995
9. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514
10. H Burgmann O Janata F Allerberger, et al. 2008 Hospital antibiotic management in Austria - results of the ABS maturity survey of the ABS International group Wien Klin Wochenschr 120 280 283 10.1007/s00508-008-0968-7 18545951 (Pubitemid 351845335)
11. KA Kierner V Gartner R Bartsch, et al. 2010 Attitudes towards palliative care in primary metastatic cancer: a survey among oncologists Wien Klin Wochenschr 122 45 49 10.1007/s00508-009-1295-3 20177859
12. K Schmid N Oehl F Wrba, et al. 2009 EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases Clin Cancer Res 15 4554 4560 1:CAS:528:DC%2BD1MXosV2lt7o%3D 10.1158/1078-0432.CCR-09- 0089 19584155
13. R Lencioni JM Llovet Dis Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver 30 52 60 10.1055/s-0030-1247132
14. M Pinter W Sieghart I Graziadei, et al. 2009 Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis Oncologist 14 70 76 10.1634/theoncologist.2008-0191 19144684
15. JM Llovet J Fuster J Bruix 2004 The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma Liver Transpl 10 S115 S120 10.1002/lt.20034 14762851
16. A Huether M Hopfner V Baradari, et al. 2007 Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma Biochem Pharmacol 73 1308 1317 1:CAS:528:DC%2BD2sXjsVGitLw%3D 10.1016/j.bcp.2006.12.031 17266941 (Pubitemid 46463952)
17. RV LaRocca MD Hicks L Mull, et al. 2007 Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report J Gastrointest Cancer 38 154 156 10.1007/s12029-008-9028-9 19089671
18. AB El-Khoueiry C Rankin HJ Lenz, et al. 2007 SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas J Clin Oncol 25 4639 Abstract 4618S
19. C Bengala F Bertolini N Malavasi, et al. 2010 Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial Br J Cancer 102 68 72 1:CAS:528:DC%2BC3cXhtFOrsw%3D%3D 10.1038/sj.bjc.6605458 19935794
20. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 1:CAS:528:DC%2BD2cXotFalsbk%3D 10.1158/0008-5472.CAN-04-1443 15466206 (Pubitemid 39331023)
21. A Tannapfel F Sommerer M Benicke, et al. 2003 Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 52 706 712 1:CAS:528:DC%2BD3sXjvVeiu7g%3D 10.1136/gut.52.5.706 12692057 (Pubitemid 36528874)